Document Detail

Transcatheter aortic valve implantation.
MedLine Citation:
PMID:  19930984     Owner:  NLM     Status:  In-Data-Review    
Aortic stenosis is the most important valvular heart disease affecting the elderly population. Surgical aortic valve replacement is the mainstay of treatment, although a substantial number of patients are considered high risk for surgery. Many of these patients do not undergo surgery and have poor outcomes from medically treated symptomatic, severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) provides a promising treatment option for some of these patients. Several devices are under investigation. The Edwards Sapien valve (Edwards Lifesciences, Irvine, CA) and the CoreValve (Medtronic, Minneapolis, MN) have the largest human experience to date. Initial data suggest that these devices have an acceptable safety profile and provide excellent hemodynamic relief of aortic stenosis. The Edwards Sapien valve is currently under investigation in the United States in the PARTNER (Placement of Aortic Transcatheter Valve) trial in high-risk surgical or inoperable patients; TAVI is available for clinical use in both Canada and Europe. TAVI is not used in low- or intermediate-risk surgical patients; however, future studies may prove its applicability in these subsets. The major complications of TAVI include access site-related problems and device malpositioning/migration. There are several new-generation prosthetic valves and delivery systems designed to be low profile and repositionable. Technical advances and refinement of the implantation methods may make TAVI even safer and ultimately a better treatment option, not only for patients with high surgical risk but also for those with moderate or low risk.
Samir R Kapadia; E Murat Tuzcu
Related Documents :
16245514 - A quadricuspid aortic valve in a patient with neurofibromatosis type 1.
19008114 - Aortic root replacement in children: a word of caution about valve-sparing procedures.
20609764 - Early and midterm hemodynamics after aortic valve bypass (apicoaortic conduit) surgery.
2341484 - Synthetic polymer tissue adhesive in the surgery of ascending aortic dissection. report...
15173734 - Solid and gaseous cerebral microembolization during off-pump, on-pump, and open cardiac...
17670054 - Multiple aneurysm of saphenous vein graft with low symptoms 16 years after coronary art...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in cardiovascular medicine     Volume:  11     ISSN:  1534-3189     ISO Abbreviation:  Curr Treat Options Cardiovasc Med     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9815942     Medline TA:  Curr Treat Options Cardiovasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  467-75     Citation Subset:  -    
E. Murat Tuzcu, MD Department of Medicine, Cleveland Clinic, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Update on Renin-Angiotensin-aldosterone blockade in heart failure.
Next Document:  Percutaneous approaches to mitral regurgitation.